In Q1 FY2026, Scholar Rock reported no revenue and a net loss of $105.5 million, a 41.2% increase from the prior year. Operating loss was $102.0 million, up 32.3%. The company held $430.5 million in cash and $276.0 million in equity, with long-term debt of $196.6 million.
•No revenue in Q1 FY2026.
•Net loss widened 41.2% to $105.5 million.
•Cash and equivalents stood at $430.5 million.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Scholar Rock Holding Corporation, a biopharmaceutical company focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases.
The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform.
This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. The company is developing Apitegromab, an inhibitor of the activation of myostatin, which is in a Phase 2 clinical trial for the treatment of SMA and facioscapulohumeral muscular dystrophy (FSHD).
Additionally, SRK-439, an anti-pro/latent myostatin antibody, is in a Phase 1 clinical trial for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. SRK-181 is a Phase 2-ready investigational inhibitor of latent TGFß1 for the treatment of patients with solid tumors that are resistant to anti-PD-(L)1 antibody therapies
Products in pre-clinical development, including SRK-373, a selective inhibitor of the latent TGFß1 isoform with selective activity in the fibrotic extracellular matrix, for the treatment of fibrotic diseases, and SRK-256, an inhibitor of RGMc, or hemojuvelin, for the treatment of iron-restricted anemias.
Scholar Rock Holding Corporation is also developing a pipeline that includes programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. Founded in 2012, Scholar Rock is headquartered in Cambridge, Massachusetts.
What does Scholar Rock Holding Corporation (SRRK) do?
Scholar Rock Holding Corporation is a biopharmaceutical company focused on developing therapies for spinal muscular atrophy (SMA) and other rare neuromuscular diseases. The company leverages a proprietary platform that targets the precursor forms of growth factors within the transforming growth factor beta (TGFß) superfamily. Its lead product candidate, Apitegromab, is an inhibitor of myostatin activation currently in Phase 2 clinical trials for SMA and facioscapulohumeral muscular dystrophy (FSHD). Other pipeline candidates include SRK-439, an anti-pro/latent myostatin antibody in Phase 1 for neuromuscular diseases; SRK-181, a Phase 2-ready inhibitor of latent TGFß1 for solid tumors resistant to anti-PD-(L)1 therapies; and preclinical programs such as SRK-373 for fibrotic diseases and SRK-256 for iron-restricted anemias.
Where is Scholar Rock (SRRK) listed and what currency does it trade in?
Scholar Rock Holding Corporation is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol SRRK. The stock trades in US Dollars (USD), as the company is based in the United States. The exchange is one of the major US stock exchanges, providing liquidity and visibility for the company's shares.
What sector and industry does Scholar Rock (SRRK) belong to?
Scholar Rock Holding Corporation operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching and developing innovative therapies for serious diseases, particularly in the areas of neuromuscular disorders and oncology. The company's work involves advanced molecular biology and monoclonal antibody development.
Where is Scholar Rock (SRRK) headquartered and what markets does it serve?
Scholar Rock Holding Corporation is headquartered in the United States, as indicated by its country and region (us). The company primarily serves the US market, focusing on developing treatments for patients with rare and severe neuromuscular diseases, as well as solid tumors. While its clinical trials may involve international sites, its core operations and regulatory focus are centered in the US.
What is Scholar Rock's (SRRK) business model and how does it generate value?
Scholar Rock operates as a biopharmaceutical company, generating value through the discovery and development of novel monoclonal antibodies that target growth factor activation. Its proprietary platform enables selective targeting of latent forms of growth factors within the TGFß superfamily. The company advances its pipeline through clinical trials, with the goal of obtaining regulatory approval and commercializing therapies for neuromuscular diseases, fibrotic diseases, and cancer. Revenue would come from product sales, licensing agreements, or partnerships, though as a development-stage company, it currently focuses on R&D.